Fibrin Glue Injection for Cavernous Sinus Hemostasis Associated with Cranial Nerve Deficit: A Case Report

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1055/s-0034-1543977</td>
</tr>
<tr>
<td>Accessed</td>
<td>September 27, 2017 3:50:24 PM EDT</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:21462111">http://nrs.harvard.edu/urn-3:HUL.InstRepos:21462111</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>

(Article begins on next page)
Fibrin Glue Injection for Cavernous Sinus Hemostasis Associated with Cranial Nerve Deficit: A Case Report

Daryoush Tavanaiepour1  Sarah Jernigan2  Mohamad Abolfotoh3  Ossama Al-Mefty4

1Department of Neurosurgery, University of Florida College of Medicine, Jacksonville, Florida, United States
2Department of Neurosurgery, University of Miami, Miami, Florida, United States
3Department of Neurosurgery, Ain Shams University, Cairo, Egypt
4Department of Neurosurgery, Brigham and Women’s Hospital and Harvard School of Medicine, Boston, Massachusetts, United States

Address for correspondence: Daryoush Tavanaiepour, MD, Department of Neurosurgery, Tower 1, 8th floor, 580 West 8th Street, Jacksonville, FL 32209 (e-mail: Daryoush.tavanaiepour@jax.ufl.edu).

Introduction

Fibrin glue injection (Baxter Healthcare Corp., Deerfield, Illinois, United States) has been used to control intraoperative cavernous sinus (CS) venous bleeding. There have been no reported complications related to this maneuver.1,2 We present a case in which a patient developed a sensory trigeminal nerve deficit after injection of fibrin glue into the posterior CS during resection of a petrosal meningioma. We believe that this deficit was due to the compression of the trigeminal ganglion (TG) similar to balloon compression procedures. Although fibrin glue injection may achieve satisfactory cavernous sinus homeostasis, the volume and rate of injection should be kept in mind to avoid a compressive lesion on traversing cranial nerves and surrounding structures, or retrograde filling of the venous tributaries.

Case Report

A 40-year-old woman with radiation-induced petrous apex meningioma underwent resection of the lesion via a posterior fossa approach. After complete resection of the lesion, the involved dura was excised to the junction of the superior petrosal sinus and the posterior wall of the CS, where venous hemorrhage ensued. This was easily controlled with injection of fibrin glue into the posterior CS. The remaining of the procedure was uneventful. Postoperatively the patient developed new-onset ipsilateral facial numbness. There was dense hypoalgesia and hypoesthesia in the trigeminal V1 and V2 distributions, and less affected, in V3. The motor trigeminal function was intact. Postoperative magnetic resonance imaging (MRI) demonstrated total gross resection; however, there was expansion of the CS by the fibrin glue. Repeated postoperative MRI at 3 months demonstrated resolution of the CS expansion (Fig. 1). However, the patient’s sensory TN deficit persisted after the 18-month follow-up.

Discussion

Multiple intraoperative techniques have been described for cavernous sinus hemostasis that include the use of Surgicel...
complete resolution of symptoms and with no sensory deficit. This procedure was associated with a recurrence rate of ~20%.³ Later, Mullan and Lichtor introduced the PBC procedure for trigeminal neuralgia.⁷

Sensory complaints associated with PBC have been well documented. In a large retrospective case series, 441 of 496 patients undergoing PBC had early facial numbness (89%). However, the facial numbness persisted for >3 months in only 23 patients (4.6%).³ Despite its prevalent use, there has been a wide variation of the PBC parameters including the amount of pressure (459–2080 mm Hg), duration (0.5–15 minutes), and volume (0.5–1.1 mL) of balloon compression.⁹ Studies have demonstrated a direct correlation between the duration of balloon compression and the development of facial numbness. Lee and Chen performed PBC in 80 patients, while keeping the other parameters stable, the duration of compression was either 60 seconds or 180 seconds. At 1-year follow-up, patients with a shorter duration of compression had lower rates of facial numbness, with similar rates of efficacy.⁹ Brown and Pilitsis also demonstrated an association between duration of PBC compression (1.18 versus 1.06 minutes) and facial numbness in 65 PBC procedures.¹⁰ Zanusso et al performed PBC with intraoperative pressure monitoring and demonstrated an association between high PBC pressure with greater side effects but with lower recurrence rates at 1 year.¹¹ Similarly, Brown and Pilitsis demonstrated a trend toward facial numbness with higher PBC pressures.¹⁰

Drawing analogies from the preceding discussion regarding PBC and TN sensory deficits, the fibrin glue injection produced a compressive lesion on the trigeminal ganglion with the resultant sensory deficit.⁶

This situation is analogous to percutaneous balloon compression (PBC) of the TG for the treatment of trigeminal neuralgia. The development of PBC for trigeminal neuralgia originated from successful reports of surgical manipulation of the TN for trigeminal neuralgia. Shelden et al performed proximal root compression at the TG that involved applying "gentle" pressure to the nerve using a blunt dissector with complete resolution of symptoms and with no sensory deficit.⁶ This procedure was associated with a recurrence rate of ~20%.³ Later, Mullan and Lichtor introduced the PBC procedure for trigeminal neuralgia.⁷

Sensory complaints associated with PBC have been well documented. In a large retrospective case series, 441 of 496 patients undergoing PBC had early facial numbness (89%). However, the facial numbness persisted for >3 months in only 23 patients (4.6%).³ Despite its prevalent use, there has been a wide variation of the PBC parameters including the amount of pressure (459–2080 mm Hg), duration (0.5–15 minutes), and volume (0.5–1.1 mL) of balloon compression.⁹ Studies have demonstrated a direct correlation between the duration of balloon compression and the development of facial numbness. Lee and Chen performed PBC in 80 patients, while keeping the other parameters stable, the duration of compression was either 60 seconds or 180 seconds. At 1-year follow-up, patients with a shorter duration of compression had lower rates of facial numbness, with similar rates of efficacy.⁹ Brown and Pilitsis also demonstrated an association between duration of PBC compression (1.18 versus 1.06 minutes) and facial numbness in 65 PBC procedures.¹⁰ Zanusso et al performed PBC with intraoperative pressure monitoring and demonstrated an association between high PBC pressure with greater side effects but with lower recurrence rates at 1 year.¹¹ Similarly, Brown and Pilitsis demonstrated a trend toward facial numbness with higher PBC pressures.¹⁰

Drawing analogies from the preceding discussion regarding PBC and TN sensory deficits, the fibrin glue injection produced a compressive lesion on the TG, similar to PBC, leading to the patient's facial numbness. In this case, the duration of TG compression was sustained for days (evident by the postoperative MRI), as compared with seconds for PBC. The amount of pressure applied to the TG by the fibrin glue injection is unknown, although it was sufficient to produce the sensory deficit without a motor deficit.

**Conclusion**

Although fibrin glue injection may achieve satisfactory cavernous sinus homeostasis, the volume and rate of injection should be kept in mind to avoid a compressive lesion on traversing cranial nerves and surrounding structures or retrograde filling of the venous tributaries.

**References**

5 Bedi AD, Toms SA, Dehdashti AR. Use of hemostatic matrix for hemostasis of the cavernous sinus during endoscopic endonasal pituitary and suprasellar tumor surgery. Skull Base 2011;21(3):189–192